NCT03139240

Brief Summary

Our primary objective will be to determine if a strong opioid, oxycodone, given at a dose recommended for severe pain in addition to ibuprofen decreases maximum pain scores compared to ibuprofen and placebo in women undergoing medical abortion (MAB). Results of this study will help future providers understand whether prescribing opioids are an important adjunct for pain control in women undergoing MAB.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
172

participants targeted

Target at P50-P75 for phase_4

Timeline
Completed

Started May 2017

Shorter than P25 for phase_4

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

April 28, 2017

Completed
3 days until next milestone

Study Start

First participant enrolled

May 1, 2017

Completed
2 days until next milestone

First Posted

Study publicly available on registry

May 3, 2017

Completed
1.1 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

May 31, 2018

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

May 31, 2018

Completed
1.2 years until next milestone

Results Posted

Study results publicly available

August 13, 2019

Completed
Last Updated

August 28, 2019

Status Verified

August 1, 2019

Enrollment Period

1.1 years

First QC Date

April 28, 2017

Results QC Date

June 6, 2019

Last Update Submit

August 18, 2019

Conditions

Outcome Measures

Primary Outcomes (3)

  • Overall Maximum Self-reported Pain Score

    Women text responses through two surveys within 24 hours after misoprostol administration indicating their maximum self-reported pain score on an 11-point Numeric Pain Rating Scale (0 = no pain, 5 = moderate pain, and 10 = worst possible pain).

    24 hours after misoprostol administration

  • <7 Weeks of Gestation - Maximum Self-reported Pain Score

    Women text responses through two surveys within 24 hours after misoprostol administration indicating their maximum self-reported pain score on an 11-point Numeric Pain Rating Scale (0 = no pain, 5 = moderate pain, and 10 = worst possible pain).

    24 hours after misoprostol administration

  • 7-10 Weeks Gestation - Maximum Self-reported Pain Score

    Women text responses through two surveys within 24 hours after misoprostol administration indicating their maximum self-reported pain score on an 11-point Numeric Pain Rating Scale (0 = no pain, 5 = moderate pain, and 10 = worst possible pain).

    24 hours after misoprostol administration

Study Arms (2)

Gestational age <7 weeks

EXPERIMENTAL

Women with a gestational age \<7 weeks will be randomized to oxycodone 10mg oral vs placebo

Drug: Oxycodone 10mg oralOther: Placebo

Gestational age 7-10w0d

EXPERIMENTAL

Women with a gestational age 7-10w0d will be randomized to oxycodone 10mg oral vs placebo

Drug: Oxycodone 10mg oralOther: Placebo

Interventions

Oxycodone 10mg oral given for pain control in addition to standard of care medications in women undergoing medical abortion

Gestational age 7-10w0dGestational age <7 weeks
PlaceboOTHER

Placebo given in addition to standard of care medications in women undergoing medical abortion

Gestational age 7-10w0dGestational age <7 weeks

Eligibility Criteria

Age18 Years - 50 Years
Sexfemale
Healthy VolunteersYes
Age GroupsAdult (18-64)

You may qualify if:

  • Aged 18 years or older
  • Seeking elective medical abortion
  • In good health
  • Pregnancy with intrauterine gestational sac up to 10 0/7 weeks, dated by ultrasound
  • Able and willing to receive text messages via phone
  • Literate in English
  • Able and willing to give informed consent and agree to the study terms
  • Have assistance at home; no motor vehicle use while taking study medications

You may not qualify if:

  • Lack of access to cell phone and texting capabilities
  • Early pregnancy failure
  • Contraindications to the study medications: Oxycodone, Ibuprofen
  • Contraindications to medical abortion with Mifepristone or Misoprostol
  • History of methadone or heroin use
  • Used alcohol in the past 24 hours
  • Used marijuana \>4 times per week
  • Any opioid in the past 30 days
  • Using additional pain medications

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Site 1

Beaverton, Oregon, 97005, United States

Location

Related Publications (1)

  • Colwill AC, Bayer LL, Bednarek P, Garg B, Jensen JT, Edelman AB. Opioid Analgesia for Medical Abortion: A Randomized Controlled Trial. Obstet Gynecol. 2019 Dec;134(6):1163-1170. doi: 10.1097/AOG.0000000000003576.

MeSH Terms

Conditions

Pain

Interventions

Oxycodone

Condition Hierarchy (Ancestors)

Neurologic ManifestationsSigns and SymptomsPathological Conditions, Signs and Symptoms

Intervention Hierarchy (Ancestors)

CodeineMorphine DerivativesMorphinansOpiate AlkaloidsAlkaloidsHeterocyclic CompoundsHeterocyclic Compounds, Bridged-RingHeterocyclic Compounds, 4 or More RingsHeterocyclic Compounds, Fused-RingPhenanthrenesPolycyclic Aromatic HydrocarbonsPolycyclic Compounds

Results Point of Contact

Title
Ob/Gyn Regulatory Specialist
Organization
Oregon Health & Science University

Publication Agreements

PI is Sponsor Employee
Yes

Study Design

Study Type
interventional
Phase
phase 4
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
PARTICIPANT, INVESTIGATOR
Masking Details
Double Blind
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
MD, Instructor

Study Record Dates

First Submitted

April 28, 2017

First Posted

May 3, 2017

Study Start

May 1, 2017

Primary Completion

May 31, 2018

Study Completion

May 31, 2018

Last Updated

August 28, 2019

Results First Posted

August 13, 2019

Record last verified: 2019-08

Data Sharing

IPD Sharing
Will not share

Locations